AZTR

Azitra, Inc.
CAPPED RATING

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Azitra, Inc. (AZTR) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.2
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -49.8%
Price Return 12M -81.9%
Catalyst Signal 0.00
Market Cap $3.8M
TTM Revenue N/A
Price / Sales N/A
ROE -256.7%

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) D+ (1.8) C (2.3) D- (1.0) C+ (2.6) C (2.3)
2026-11-10 A- (3.9) C- (1.9) C (2.3) D- (1.1) C+ (2.6) C (2.3)
2026-11-03 B+ (3.7) D+ (1.8) C (2.4) D (1.3) C+ (2.7) C (2.4)
2026-10-27 C+ (2.5) C- (1.9) C (2.4) C (2.3) C+ (2.6) C (2.3)
2026-10-20 B+ (3.7) D+ (1.8) C (2.4) D (1.4) C+ (2.6) C (2.4)
Page 1 of 3